Aquestive Therapeutics Faces Securities Fraud Lawsuit After FDA Delay Concerns and Analyst Downgrades
Aquestive Therapeutics (AQST) shares fell sharply after the FDA identified deficiencies in its Anaphylm NDA, leading to a 47% price target cut by Cantor and a potential securities fraud class action. Investors who purchased between June 16, 2025, and January 8, 2026, lost over 37% of their investment value. Analysts had previously been optimistic about FDA approval by January 31, 2026.
Tickers: $AQST
Topics: analyst opinion Anaphylm Aquestive Therapeutics FDA lawsuit price target downgrade stock loss